

Vidal Essebag

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7232299/publications.pdf>

Version: 2024-02-01

110
papers

4,871
citations

147801

31
h-index

98798

67
g-index

110
all docs

110
docs citations

110
times ranked

4975
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative effectiveness of ventricular tachycardia ablation vs. escalated antiarrhythmic drug therapy by location of myocardial infarction: a sub-study of the VANISH trial. <i>Europace</i> , 2022, 24, 948-958.	1.7	1
2	Ventricular tachycardia characteristics and outcomes with catheter ablation vs. antiarrhythmic therapy: insights from the VANISH trial. <i>Europace</i> , 2022, 24, 1112-1118.	1.7	4
3	Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS 2 Score: Insights From the BRAIN-AF Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2022, , CIRCEP121010462.	4.8	3
4	Randomized Ablation-Based Rhythm-Control Versus Rate-Control Trial in Patients With Heart Failure and Atrial Fibrillation: Results from the RAFT-AF trial. <i>Circulation</i> , 2022, 145, 1693-1704.	1.6	54
5	Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2021, 384, 305-315.	27.0	417
6	Fusion pacing in patients with right bundle branch block who undergo cardiac resynchronization therapy. <i>Journal of Electrocardiology</i> , 2021, 64, 66-71.	0.9	6
7	Non-vitamin K Antagonists and Cardiac Implantable Electronic Devices. , 2021, , 211-223.		0
8	Direct Oral Anticoagulants and Atrial Fibrillation Ablation. , 2021, , 225-234.		0
9	Canadian Registry of Electronic Device Outcomes: remote monitoring outcomes in the Abbott battery performance alert—a multicentre cohort. <i>Europace</i> , 2021, 23, 1319-1323.	1.7	2
10	A randomized ablation-based atrial fibrillation rhythm control versus rate control trial in patients with heart failure and high burden atrial fibrillation: The RAFT-AF trial rationale and design. <i>American Heart Journal</i> , 2021, 234, 90-100.	2.7	20
11	Post-operative pain following cardiac implantable electronic device implantation: insights from the BRUISE CONTROL trials. <i>Europace</i> , 2021, 23, 748-756.	1.7	7
12	Impact of Choice of Prophylaxis on the Microbiology of Cardiac Implantable Electronic Device Infections: Insights From the Prevention of Arrhythmia Device Infection Trial (PADIT). <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab513.	0.9	4
13	Sustained quality-of-life improvement post-cryoballoon ablation in patients with paroxysmal atrial fibrillation: Results from the STOP-AF Post-Approval Study. <i>Heart Rhythm</i> , 2020, 17, 485-491.	0.7	10
14	2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Position Statement on the Management of Ventricular Tachycardia and Fibrillation in Patients With Structural Heart Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 822-836.	1.7	28
15	Optimization of Chronic Cardiac Resynchronization Therapy Using Fusion Pacing Algorithm Improves Echocardiographic Response. <i>CJC Open</i> , 2020, 2, 62-70.	1.5	9
16	Long-term outcomes of catheter ablation for atrial fibrillation: It's a matter of time. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1048-1050.	1.7	0
17	Population-Level Sex Differences and Predictors for Treatment With Catheter Ablation in Patients With Atrial Fibrillation and Heart Failure. <i>CJC Open</i> , 2020, 2, 85-93.	1.5	3
18	Mortality Risk Increases With Clustered Ventricular Arrhythmias in Patients With Implantable Cardioverter-Defibrillators. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 327-337.	3.2	15

#	ARTICLE	IF	CITATIONS
19	Catheter Ablation of Atrial Fibrillation: Current and Evolving Indications. Canadian Journal of Cardiology, 2020, 36, 1685-1689.	1.7	5
20	Major Adverse Cardiovascular Events Associated With Postoperative Atrial Fibrillation After Noncardiac Surgery. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007437.	4.8	49
21	Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. Europace, 2020, 22, 739-747.	1.7	10
22	Cardiac resynchronization therapy reprogramming to improve electrical synchrony in patients with existing devices. Journal of Electrocardiology, 2019, 56, 94-99.	0.9	13
23	Population-level evaluation of complications after catheter ablation in patients with atrial fibrillation and heart failure. Journal of Cardiovascular Electrophysiology, 2019, 30, 2678-2685.	1.7	4
24	Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007545.	4.8	25
25	Incidence and Predictors of Intracardiac Thrombus on Pre-electrophysiological Procedure Transesophageal Echocardiography. CJC Open, 2019, 1, 231-237.	1.5	6
26	Subclinical Atrial Fibrillation and Risk of Stroke: Past, Present and Future. Medicina (Lithuania), 2019, 55, 611.	2.0	21
27	Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovascular Disorders, 2019, 19, 18.	1.7	47
28	Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design. Canadian Journal of Cardiology, 2019, 35, 1069-1077.	1.7	27
29	Concomitant anti-platelet therapy in warfarin-treated patients undergoing cardiac rhythm device implantation: A secondary analysis of the BRUISE CONTROL trial. International Journal of Cardiology, 2019, 288, 87-93.	1.7	10
30	Maximizing biventricular pacing in patients with rate-controlled atrial fibrillation using ventricular sense response. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1069-1072.	1.2	2
31	Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients. Pharmacological Research, 2019, 143, 133-142.	7.1	5
32	Predicting response to cardiac resynchronization therapy: Use of strict left bundle branch block criteria. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 431-438.	1.2	10
33	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. Journal of the American College of Cardiology, 2019, 74, 2845-2854.	2.8	94
34	Long-Term Outcomes After Ablation for Paroxysmal Atrial Fibrillation Using the Second-Generation Cryoballoon. JACC: Clinical Electrophysiology, 2019, 5, 306-314.	3.2	72
35	Implantable cardioverter-defibrillator use in elderly patients receiving cardiac resynchronization: A meta-analysis. Hellenic Journal of Cardiology, 2019, 60, 276-281.	1.0	9
36	The use of adenosine to identify dormant conduction after accessory pathway ablation: a single center experience and literature review. American Journal of Cardiovascular Disease, 2019, 9, 84-90.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Differentiating Ventricular From Supraventricular Arrhythmias Using the Postpacing Interval After Failed Antitachycardia Pacing. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005921.	4.8	2
38	Meta-Analysis Comparing Neurohumoral Antagonist Use in Patients ≥ 75 Years Versus < 75 Years Receiving Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2018, 121, 975-980.	1.6	1
39	Defining the pattern of initiation of monomorphic ventricular tachycardia using the beat-to-beat intervals recorded on implantable cardioverter defibrillators from the RAFT study: A computer-based algorithm. <i>Journal of Electrocardiology</i> , 2018, 51, 470-474.	0.9	4
40	The Optimal Anti-Coagulation for Enhanced-Risk Patients Post-Catheter Ablation for Atrial Fibrillation (OCEAN) trial. <i>American Heart Journal</i> , 2018, 197, 124-132.	2.7	50
41	Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2018, 11, e005663.	4.8	18
42	Cost Effectiveness of Ventricular Tachycardia Ablation Versus Escalation of Antiarrhythmic Drug Therapy. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 660-668.	3.2	27
43	Assessment and Management of the Left Atrial Appendage Thrombus in Patients With Nonvalvular Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2018, 34, 252-261.	1.7	58
44	Canadian Registry of Implantable Electronic Device Outcomes: Longer-term follow-up of the Riata lead under advisory. <i>Heart Rhythm</i> , 2018, 15, 524-529.	0.7	4
45	Prevention of Arrhythmia Device Infection Trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3098-3109.	2.8	160
46	Prevention of venous thrombosis after electrophysiology procedures: a survey of national practice. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 53, 357-363.	1.3	5
47	Pulmonary embolism after electrophysiology procedures: Incidence from a single centre registry. <i>Thrombosis Research</i> , 2018, 167, 125-127.	1.7	1
48	Long-term risk of stroke and bleeding post-atrial fibrillation ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1355-1362.	1.7	15
49	Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2). <i>European Heart Journal</i> , 2018, 39, 3973-3979.	2.2	131
50	Prognostic Value of Noninducibility on Outcomes of Ventricular Tachycardia Ablation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 911-919.	3.2	12
51	Canadian Registry of Implantable Electronic Device Outcomes: Surveillance of High-Voltage Leads. <i>Canadian Journal of Cardiology</i> , 2018, 34, 808-811.	1.7	2
52	Wound haematoma following defibrillator implantation: incidence and predictors in the Shockless Implant Evaluation (SIMPLE) trial. <i>Europace</i> , 2017, 19, euw116.	1.7	20
53	Catheter ablation for the treatment of atrial fibrillation is associated with a reduction in health care resource utilization. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 733-741.	1.7	18
54	Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 582-587.	1.6	8

#	ARTICLE	IF	CITATIONS
55	Cardiac Resynchronization Therapy Reduces Ventricular Arrhythmias in Primary but Not Secondary Prophylactic Implantable Cardioverter Defibrillator Patients. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	4.8	31
56	Short-term dabigatran interruption before cardiac rhythm device implantation: multi-centre experience from the RE-LY trial. <i>Europace</i> , 2017, 19, 1630-1636.	1.7	16
57	Population-Based Evaluation of Major Adverse Events After Catheter Ablation for Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1425-1433.	3.2	14
58	Venous Thrombosis After Electrophysiology Procedures. <i>Chest</i> , 2017, 152, 574-586.	0.8	19
59	Canadian Cardiovascular Society/Canadian Heart Rhythm Society 2016 Implantable Cardioverter-Defibrillator Guidelines. <i>Canadian Journal of Cardiology</i> , 2017, 33, 174-188.	1.7	84
60	Pattern of initiation of monomorphic ventricular tachycardia and implications on tachycardia mechanism. <i>Minerva Cardiology and Angiology</i> , 2017, 65, 357-368.	0.7	1
61	Abstract 21033: Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A Vanish Substudy. <i>Circulation</i> , 2017, 136, .	1.6	0
62	Recent advances in ablation of ventricular tachycardia associated with structural heart disease. <i>Current Opinion in Cardiology</i> , 2016, 31, 64-71.	1.8	13
63	A Historical Perspective on the Role of Functional Lines of Block in the Reentrant Circuit of Ventricular Tachycardia. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 490-496.	1.2	9
64	Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. <i>New England Journal of Medicine</i> , 2016, 375, 111-121.	27.0	616
65	Therapy for ventricular arrhythmias in structural heart disease: a multifaceted challenge. <i>Journal of Physiology</i> , 2016, 594, 2431-2443.	2.9	12
66	Diagnosis and management of supraventricular tachycardias. <i>Cmaj</i> , 2016, 188, E466-E473.	2.0	19
67	Implications of Frailty in Elderly Patients With Electrophysiological Conditions. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 288-294.	3.2	22
68	Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1300-1308.	2.8	154
69	Management of antithrombotic therapy during cardiac implantable device surgery. <i>Journal of Arrhythmia</i> , 2016, 32, 163-169.	1.2	19
70	Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. <i>American Heart Journal</i> , 2016, 173, 102-107.	2.7	34
71	Prognostic value of pulmonary vein size in prediction of atrial fibrillation recurrence after pulmonary vein isolation: a cardiovascular magnetic resonance study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2015, 17, 49.	3.3	24
72	Warfarin Treatment and Outcomes of Patients With Atrial Fibrillation in Rural and Urban Settings. <i>Journal of Rural Health</i> , 2015, 31, 310-315.	2.9	15

#	ARTICLE	IF	CITATIONS
73	Psychological effects of implantable cardioverter defibrillator shocks. A review of study methods. <i>Frontiers in Psychology</i> , 2015, 6, 39.	2.1	25
74	The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1207-1218.	1.7	43
75	Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients) <i>TJ ETQq1 1 0.784314 198T /Ov</i>	1.7	43
76	A Systematic Review on the Progression of Paroxysmal to Persistent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 105-115.	3.2	63
77	Temporal trends and sex differences in pulmonary vein isolation for patients with atrial fibrillation. <i>Heart Rhythm</i> , 2015, 12, 1979-1986.	0.7	60
78	Substrate-guided ablation of haemodynamically tolerated and intolerated ventricular tachycardia in patients with structural heart disease: effect of cardiomyopathy type and acute success on long-term outcome. <i>Europace</i> , 2015, 17, 461-467.	1.7	62
79	A Systematic Review and Meta-analysis of the Association Between Implantable Cardioverter-Defibrillator Shocks and Long-term Mortality. <i>Canadian Journal of Cardiology</i> , 2015, 31, 270-277.	1.7	69
80	Cost Effectiveness of Continued-Warfarin Versus Heparin-Bridging Therapy During Pacemaker and Defibrillator Surgery. <i>Journal of the American College of Cardiology</i> , 2015, 65, 957-959.	2.8	13
81	Incidence, Predictors, and Procedural Results of Upgrade to Resynchronization Therapy. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 152-158.	4.8	29
82	Meta-Analysis of Continuous Oral Anticoagulants Versus Heparin Bridging in Patients Undergoing CIED Surgery: Reappraisal after the BRUISE Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 417-423.	1.2	36
83	Response to Letter Regarding Article, "Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis". <i>Circulation</i> , 2014, 130, e428-9.	1.6	2
84	Prognostic value of atrial fibrillation inducibility after right atrial flutter ablation. <i>Heart Rhythm</i> , 2014, 11, 1870-1876.	0.7	18
85	Management of Anticoagulation Around Pacemaker and Defibrillator Surgery. <i>Circulation</i> , 2014, 129, 2062-2065.	1.6	24
86	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. <i>Canadian Journal of Cardiology</i> , 2014, 30, 231-236.	1.7	35
87	Relation of Digoxin Use in Atrial Fibrillation and the Risk of All-Cause Mortality in Patients ≥ 65 Years of Age With Versus Without Heart Failure. <i>American Journal of Cardiology</i> , 2014, 114, 401-406.	1.6	55
88	Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Implementation. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1346-1360.	1.7	22
89	Anticoagulation Management Pre- and Post Atrial Fibrillation Ablation: A Survey of Canadian Centres. <i>Canadian Journal of Cardiology</i> , 2013, 29, 219-223.	1.7	37
90	Pacemaker or Defibrillator Surgery without Interruption of Anticoagulation. <i>New England Journal of Medicine</i> , 2013, 368, 2084-2093.	27.0	482

#	ARTICLE	IF	CITATIONS
91	Comparative Effectiveness of Rhythm Control vs Rate Control Drug Treatment Effect on Mortality in Patients With Atrial Fibrillation. Archives of Internal Medicine, 2012, 172, 997-1004.	3.8	126
92	Nonphysiologic noise early after defibrillator implantation in Canada: Incidence and implications. Heart Rhythm, 2012, 9, 378-382.	0.7	7
93	Trends in US Hospitalization Rates and Rhythm Control Therapies Following Publication of the AFFIRM and RACE Trials. Journal of Cardiovascular Electrophysiology, 2011, 22, 548-553.	1.7	25
94	Complications Associated With Revision of Sprint Fidelis Leads. Circulation, 2010, 121, 2384-2387.	1.6	88
95	Guidance for catheter ablation of ventricular arrhythmia. Medical and Biological Engineering and Computing, 2009, 47, 241-243.	2.8	5
96	Formation of a national network for rapid response to device and lead advisories: The Canadian Heart Rhythm Society Device Advisory Committee. Canadian Journal of Cardiology, 2009, 25, 403-405.	1.7	7
97	Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: Wide variability of perioperative bridging in Canada. Heart Rhythm, 2009, 6, 1276-1279.	0.7	33
98	Utilization of a national network for rapid response to the Medtronic Fidelis lead advisory: The Canadian Heart Rhythm Society Device Advisory Committee. Heart Rhythm, 2009, 6, 474-477.	0.7	22
99	Bridge or continue Coumadin for device surgery: a randomized controlled trial rationale and design. Current Opinion in Cardiology, 2009, 24, 82-87.	1.8	31
100	Sex Differences in the Relationship Between Amiodarone Use and the Need for Permanent Pacing in Patients With Atrial Fibrillation. Archives of Internal Medicine, 2007, 167, 1648.	3.8	33
101	Effectiveness of catheter ablation of atrial fibrillationThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2006, 27, 130-131.	2.2	10
102	Bi-directional electrical pulmonary vein isolation as an endpoint for ablation of paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2006, 17, 111-117.	1.3	23
103	Frequency and Causes of Implantable Cardioverter-Defibrillator Therapies: Is Device Therapy Proarrhythmic?. American Journal of Cardiology, 2006, 97, 1255-1261.	1.6	212
104	Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Medical Research Methodology, 2005, 5, 5.	3.1	191
105	Left atrial ablation pendulum swinging back towards the pulmonary veinsThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal, 2005, 26, 2484-2486.	2.2	23
106	Non-inducibility post-pulmonary vein isolation achieving exit block predicts freedom from atrial fibrillation. European Heart Journal, 2005, 26, 2550-2555.	2.2	89
107	Effect of Amiodarone Dose on the Risk of Permanent Pacemaker Insertion. PACE - Pacing and Clinical Electrophysiology, 2004, 27, 1519-1525.	1.2	8
108	Expanding indications for defibrillators after myocardial infarction: risk stratification and cost effectiveness. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 43-48.	1.0	18

#	ARTICLE	IF	CITATIONS
109	The nested case-control study in cardiology. American Heart Journal, 2003, 146, 581-590.	2.7	145
110	Air Medical Transport of Cardiac Patients *. Chest, 2003, 124, 1937-1945.	0.8	51